论文部分内容阅读
LAK细胞的抗肿瘤抗转移作用已在动物实验和临床研究中得到证实。目前,临床上多采用患者自身的外周血淋巴细胞作为LAK前体细胞的来源。为了诱导出足够数量的具有LAK活性的细胞,需要反复分离外周血。这会使机体发生贫血,血小板减少和感染等副作用。在肿瘤的手术治疗中,常将肿瘤引流区淋巴结和原发肿块一起切除。清除的淋巴结中含有大量的淋巴细胞,若能使这些细胞获得LAK样活性并用于自体回输,不但可以增加LAK细胞的来源、防止由于反复分离外周血所
The antitumor and anti-metastatic effects of LAK cells have been confirmed in animal experiments and clinical studies. At present, the patient’s own peripheral blood lymphocytes are frequently used as a source of LAK precursor cells. In order to induce a sufficient number of cells with LAK activity, it is necessary to repeatedly separate peripheral blood. This can cause side effects such as anemia, thrombocytopenia and infection. In the surgical treatment of tumors, the tumor draining lymph nodes are often removed together with the primary tumor. Clear lymph nodes contain a large number of lymphocytes, if these cells can obtain LAK-like activity and used for autologous reinfusion, not only can increase the source of LAK cells, and prevent repeated separation of peripheral blood.